Calliditas entered 2024 with a strong Tarpeyo patient enrollment.
Ascelia achieved the vital objective to secure a re-reader evaluation of SPARKLE by May 2024.
Redeye states the report was below expecations across the board.
Redeye’s near-term forecasts are now a little lower, following a rather slow run-up to the year.
CapMan's Q1 came in significantly above LSEG Data & Analytics consensus expectations, mostly explain...
MTI Investment SE (”MTI” eller ”Bolaget”) meddelade den 2 maj 2024 att Bolaget har ingått villkorade...
Even excluding positive one-offs, the start of the year was satisfactory as Q1 is a low-season quart...
Raute’s Q1 results were a bit better than we estimated despite certain operational issues caused by ...
CapMan's turnover in Q1 amounted to EUR 18.4m, above our estimates and consensus (EUR 14.
Redeye strengthens its positive view of Transtema following the pan-Nordic support and maintenance d...
EcoRub (”EcoRub” eller ”bolaget”) publicerade den 2 maj 2024 bolagets delårsrapport för det första k...
Redeye comments on W5 Q1-results which came in slightly below our expectations while the order intak...
Redeye was hoping for higher top-line growth. But Q1 is historically a slow quarter, and we don’t kn...
Redeye comments on Sleep Cycle's Q1 2024 report, which showed a growth rate of 13% y/y (11% currency...
Muted quarter with work in progress NEX-22 Ph 1 approval and start exp.
Redeye updates Spago Nanomedical after reporting the Q1 result.
Preliminära siffror visar på magnituden av Googles uppdatering Raketech har släppt preliminära siffr...
Svaga intäkter men god kostnadskontroll förbättrar resultatet Midsummer rapporterade en svag nettoom...
Redeye states the report exceeded expectations, partly due to an equipment order worth SEK5m recogni...